Pharmacology and Toxicology for Therapeutics Program (PTTP)

The Pharmacology and Toxicology for Therapeutics Program (PTTP) is a Master Indefinite Delivery/Indefinite Quantity (IDIQ) contract awarded by the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), to support preclinical drug development services. The contract focuses on comprehensive pharmacokinetic, toxicological, and safety assessments for promising therapeutic candidates, enabling rigorous evaluation of potential new treatments before clinical trials. The IDIQ vehicle provides a flexible mechanism for NINDS to procure specialized research services to support drug discovery and development across various neurological and pharmaceutical research domains.

The task orders under this IDIQ are predominantly awarded to non-profit research institutes, with SRI International being the most frequent prime contractor, followed by Southern Research Institute. Typical task orders range from $179,557 to $7,323,160 and have performance periods spanning 18-36 months, consistently utilizing a cost-plus-fixed-fee pricing structure. The work primarily involves conducting Good Laboratory Practice (GLP) toxicology studies, pharmacokinetic assessments in rodent and non-rodent models, and specialized research supporting Investigational New Drug (IND) enabling studies. None of the task orders have small business set-aside designations, and the primary place of performance has been in California, specifically West Menlo Park. The funding consistently comes from NIH components, including the National Institute of Neurological Disorders and Stroke and the National Institute on Drug Abuse.